Author(s)

Ollo Da^1,2*, Aoua Semde^2,3, Arnaud Kouraogo^1,2, Emmanuel Zongo¹, Amidou Sawadogo³, Aristide Zongo¹, Fatou Gueye Tall⁴, Souleymane Fofana⁵, Sanata Bamba^1,2, Georges Anicet Ouedraogo⁶

¹Department of Medical Biochemistry, Center Hospital University Souro SANOU, Bobo-Dioulasso, Burkina Faso.
²Higher Institute of Health Sciences (INSSA), Nazi BONI University (UNB), Bobo-Dioulasso, Burkina Faso.
³Nephrology-Dialysis Department, Center Hospital University Souro SANOU, Bobo-Dioulasso, Burkina Faso.
⁴Department of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy and Odontostomatology, Cheikh Anta Diop University, Dakar, Senegal.
⁵Department of Pharmacy, Center Hospital University Souro SANOU, Bobo-Dioulasso, Burkina Faso.
⁶Laboratory of Research in Health Science and Animal Biotechnology (LARESBA), Nazi BONI University (UNB), Bobo-Dioulasso, Burkina Faso.

Patients living with chronic kidney disease (CKD) are at high risk of cardiovascular events. Our aim in this study was to assess the cut-off value for lipoprotein (a) (Lp(a)) in CKD patients with a history of cardiovascular disease (CVD). This was a cross-sectional study. Variables including age, sex, history of CVD, body mass index and CKD stage, were collected during CKD patient’s first admission in the nephrology dialysis department. Blood samples were collected for quantitative determination of Lp(a) by immunoturbidimetric method. They were divided into two groups: CKD patients without history of CVD and CKD patients with history of CVD. Fisher’s exact test was used to assess associations with a significance level of 0.05%. Area under the curve (AUC) and new cut-off value for Lp(a) were identified by drawing Receiver Operating Characteristic (ROC) curve. A total of seventy CKD patients with median age of 43 years [minimum-maximum = 15 - 78 years] were included. Patients with history of CVD were 65.71% (46/70). New Lp(a) cut-off point in CKD patients with history of CVD was 66.50 nmol/L [sensitivity, 87.00%; specificity, 58.30%; AUC = 0.727; p = 0.000]. ROC curve demonstrated good performance of Lp(a) to screen CKD patients with history of CVD. Further research is needed to determine an LPA gene polymorphism’s contribution to increasing risk for CVD at each kidney disease stage.

Lipoprotein (a), Cut-Off, Chronic Kidney Disease, Cardiovascular Disease

Da, O. , Semde, A. , Kouraogo, A. , Zongo, E. , Sawadogo, A. , Zongo, A. , Tall, F. , Fofana, S. , Bamba, S. and Ouedraogo, G. (2023) Lipoprotein (a) Cut-Off in Chronic Kidney Disease Patients with a History of Cardiovascular Disease in Center Hospital University Souro SANOU, Burkina Faso. Advances in Biological Chemistry, 13, 228-235. doi: 10.4236/abc.2023.136016.